{"id":17288,"date":"2024-12-09T17:39:46","date_gmt":"2024-12-09T09:39:46","guid":{"rendered":"https:\/\/flcube.com\/?p=17288"},"modified":"2024-12-10T12:13:00","modified_gmt":"2024-12-10T04:13:00","slug":"jiaxing-faber-xintian-pharma-secures-rmb-100-million-in-series-a2-financing-for-radiopharmaceuticals-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17288","title":{"rendered":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion"},"content":{"rendered":"\n

China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.<\/p>\n\n\n\n

Investment to Accelerate Pipeline R&D and Plant Construction<\/strong>
The proceeds from this financing round will be directed towards the research and development of Faber Xintian Pharma\u2019s pipeline and the construction of a radiopharmaceuticals plant. This strategic investment is expected to strengthen the company\u2019s position in the radiopharmaceuticals sector and enhance its capabilities in developing innovative treatments.<\/p>\n\n\n\n

Support from Key Industry and Government Entities<\/strong>
The support from leading industry players and government entities underscores the significance of Faber Xintian Pharma\u2019s work in the field of radiopharmaceuticals. The investment not only provides the necessary capital for expansion but also validates the company\u2019s potential to contribute to the advancement of nuclear medicine and related therapies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a…<\/p>\n","protected":false},"author":1,"featured_media":17290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,2672],"class_list":["post-17288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-pharbers-genesis"],"yoast_head":"\nJiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiaxing Faber Xintian Pharmaceutical Technology Co., Ltd has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17288\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion\" \/>\n<meta property=\"og:description\" content=\"China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17288\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T09:39:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T04:13:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion\",\"datePublished\":\"2024-12-09T09:39:46+00:00\",\"dateModified\":\"2024-12-10T04:13:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0999.png\",\"keywords\":[\"Finance\",\"Pharbers Genesis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17288#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17288\",\"name\":\"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0999.png\",\"datePublished\":\"2024-12-09T09:39:46+00:00\",\"dateModified\":\"2024-12-10T04:13:00+00:00\",\"description\":\"China-based Jiaxing Faber Xintian Pharmaceutical Technology Co., Ltd has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17288\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0999.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0999.png\",\"width\":1080,\"height\":607,\"caption\":\"Jiaxing Faber Xintian Pharma Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17288#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion - Insight, China's Pharmaceutical Industry","description":"China-based Jiaxing Faber Xintian Pharmaceutical Technology Co., Ltd has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17288","og_locale":"en_US","og_type":"article","og_title":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion","og_description":"China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.","og_url":"https:\/\/flcube.com\/?p=17288","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-09T09:39:46+00:00","article_modified_time":"2024-12-10T04:13:00+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17288#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17288"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion","datePublished":"2024-12-09T09:39:46+00:00","dateModified":"2024-12-10T04:13:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17288"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17288#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","keywords":["Finance","Pharbers Genesis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17288#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17288","url":"https:\/\/flcube.com\/?p=17288","name":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17288#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17288#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","datePublished":"2024-12-09T09:39:46+00:00","dateModified":"2024-12-10T04:13:00+00:00","description":"China-based Jiaxing Faber Xintian Pharmaceutical Technology Co., Ltd has reportedly raised RMB 100 million (USD 13.74 million) in a Series A2 financing round. The round was led by the Beijing Isotope and Radiation Innovative Industry Investment Fund, which was initiated by China National Nuclear Corporation (CNNC) and China Isotope and Radiation Corporation, with participation from the National Military-Civilian Integration Fund and Beijing local government.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17288#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17288"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17288#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","width":1080,"height":607,"caption":"Jiaxing Faber Xintian Pharma Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17288#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0999.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17288"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17288\/revisions"}],"predecessor-version":[{"id":17355,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17288\/revisions\/17355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17290"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}